ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Ono Pharmaceutical and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Ono PharmaceuticalBristol-Myers Squibb
studies on the registry1572,184
open to participants now25155
phase 3 studies under way1182
reach primary completion within a year1267
programswith a study of their own in two years1658+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOno PharmaceuticalBristol-Myers Squibb
Phase 1

Ono Pharmaceutical: 5 of its 16 programs at phase 1

  1. GCN2 Activator DCC-2812phase 1
  2. ONO-3310phase 1
  3. ONO-6414phase 1
  4. ONO-7428phase 1
  5. ONO-7429phase 1
31%

Bristol-Myers Squibb: 17 of its 58 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

29%
Phase 2

Ono Pharmaceutical: 4 of its 16 programs at phase 2

  1. ONO-4538HSCphase 2
  2. ONO-2020phase 2
  3. ONO-4915phase 2
  4. ONO-1110phase 2
25%

Bristol-Myers Squibb: 18 of its 58 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 13 more — sign in to see them all

31%
Phase 3

Ono Pharmaceutical: 7 of its 16 programs at phase 3

  1. vimseltinibphase 3
  2. Nivolumabphase 3
  3. BMS-986310phase 3
  4. tirabrutinibphase 3
  5. ripretinibphase 3

and 2 more — sign in to see them all

44%

Bristol-Myers Squibb: 16 of its 58 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies00%

Bristol-Myers Squibb: 7 of its 58 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Ono Pharmaceutical3 readouts · 1 phase 3·

Ono Pharmaceutical, Dec ’26: 2 programs whose next study reaches primary completion

  1. vimseltinibphase 3 · Dec 0 · NCT07744802
  2. ONO-2020phase 2 · Dec 31 · NCT06803823
········

Ono Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tirabrutinibphase 3 · Sep 30 · NCT06696716
·
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Ono Pharmaceutical

New programs 1

  • ONO-4915phase 2 · first study · Sep 3 · Sjogren's Syndrome

Reached a new phase 2

  • ONO-2808phase 3 · Sep 13 · Multiple System Atrophy
  • BMS-986310phase 3 · Sep 9 · Stomach Neoplasms

Study stopped 0

None

Primary completion later 1

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionOno PharmaceuticalBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungboth · compare here

Ono Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Nivolumabphase 3
  2. BMS-986310phase 3

Their studies: Ono Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Alzheimer Diseaseboth · compare here

Ono Pharmaceutical in Alzheimer Disease: 1 program

  1. ONO-2020phase 2

Their studies: Ono Pharmaceutical’s studies of Alzheimer Disease in search

Bristol-Myers Squibb in Alzheimer Disease: 5 programs

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. xanomelineapproved, new study
  4. trospiumapproved, new study
  5. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Alzheimer Disease in search

Carcinoma, Hepatocellularboth · compare here

Ono Pharmaceutical in Carcinoma, Hepatocellular: 1 program

  1. Nivolumabphase 3

Their studies: Ono Pharmaceutical’s studies of Carcinoma, Hepatocellular in search

Bristol-Myers Squibb in Carcinoma, Hepatocellular: 4 programs

  1. pumitamigphase 3
  2. Actinium Ac 225 GPC3-targeted Peptide RYZ801phase 2
  3. Nivolumabapproved, new study
  4. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Hepatocellular in search

Carcinoma, Renal Cellboth · compare here

Ono Pharmaceutical in Carcinoma, Renal Cell: 2 programs

  1. Nivolumabphase 3
  2. GCN2 Activator DCC-2812phase 1

Their studies: Ono Pharmaceutical’s studies of Carcinoma, Renal Cell in search

Bristol-Myers Squibb in Carcinoma, Renal Cell: 3 programs

  1. BMS-986527phase 1
  2. Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506phase 1
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Renal Cell in search

Colorectal Neoplasmsboth · compare here

Ono Pharmaceutical in Colorectal Neoplasms: 2 programs

  1. Nivolumabphase 3
  2. BMS-986310phase 3

Their studies: Ono Pharmaceutical’s studies of Colorectal Neoplasms in search

Bristol-Myers Squibb in Colorectal Neoplasms: 3 programs

  1. pumitamigphase 3
  2. adagrasibphase 3
  3. Nivolumabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colorectal Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Ono Pharmaceutical in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. tirabrutinibphase 3

Their studies: Ono Pharmaceutical’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Bristol-Myers Squibb in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. lisocabtagene maraleucelphase 3
  2. Cyclophosphamidephase 2
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Lymphoma, Non-Hodgkinboth · compare here

Ono Pharmaceutical in Lymphoma, Non-Hodgkin: 1 program

  1. tirabrutinibphase 3

Their studies: Ono Pharmaceutical’s studies of Lymphoma, Non-Hodgkin in search

Bristol-Myers Squibb in Lymphoma, Non-Hodgkin: 3 programs

  1. golcadomidephase 3
  2. lisocabtagene maraleucelphase 3
  3. fludarabinephase 1

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, Non-Hodgkin in search

Melanomaboth · compare here

Ono Pharmaceutical in Melanoma: 1 program

  1. Nivolumabphase 3

Their studies: Ono Pharmaceutical’s studies of Melanoma in search

Bristol-Myers Squibb in Melanoma: 2 programs

  1. Nivolumabapproved, new study
  2. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Melanoma in search

Colitis, Ulcerativeboth · compare here

Ono Pharmaceutical in Colitis, Ulcerative: 1 program

  1. ONO-6414phase 1

Their studies: Ono Pharmaceutical’s studies of Colitis, Ulcerative in search

Bristol-Myers Squibb in Colitis, Ulcerative: 1 program

  1. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Colitis, Ulcerative in search

Depressive Disorder, Majorboth · compare here

Ono Pharmaceutical in Depressive Disorder, Major: 1 program

  1. ONO-1110phase 2

Their studies: Ono Pharmaceutical’s studies of Depressive Disorder, Major in search

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

Stomach Neoplasmsboth · compare here

Ono Pharmaceutical in Stomach Neoplasms: 1 program

  1. BMS-986310phase 3

Their studies: Ono Pharmaceutical’s studies of Stomach Neoplasms in search

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

Thalassemiaboth · compare here

Ono Pharmaceutical in Thalassemia: 1 program

  1. sapablursenphase 3

Their studies: Ono Pharmaceutical’s studies of Thalassemia in search

Bristol-Myers Squibb in Thalassemia: 1 program

  1. Digoxinphase 1

Their studies: Bristol-Myers Squibb’s studies of Thalassemia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetOno PharmaceuticalBristol-Myers Squibb
PDCD1Nivolumabruleatigotatug, Nivolumabrule
A target, or a pathogen for a vaccine, known for: Ono Pharmaceutical 7 of 16 · Bristol-Myers Squibb 33 of 58 programs (23 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).